SCHEMBL19243441

SCHEMBL19243441

CC(C)CN(c1ccc(C2(C(=O)O)CCC2)cc1NC(=O)C(C)C)C1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 17/20 0.46
PIK3CD O00329 1/20 0.34
ALDH1A1 P00352 1/20 0.34
APP P05067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19243455 0.92 IDO1 (0.40) IDO1PIK3CD
SCHEMBL19243593 0.90 IDO1 (0.48) IDO1PIK3CDALDH1A1APP
SCHEMBL19243672 0.87 IDO1 (0.46) IDO1PIK3CDALDH1A1APP
SCHEMBL19243388 0.86 IDO1 (0.47) IDO1
SCHEMBL19243596 0.86 IDO1 (0.47) IDO1PIK3CDALDH1A1
SCHEMBL19243651 0.86 IDO1 (0.44) IDO1ALDH1A1
SCHEMBL19243390 0.86 IDO1 (0.60) IDO1
SCHEMBL19243486 0.86 IDO1 (0.48) IDO1
SCHEMBL19243376 0.84 IDO1 (0.60) IDO1
SCHEMBL19243398 0.84 IDO1 (0.44) IDO1PIK3CDAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338373-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC 2023-10-26 US disclosed
US-20220054486-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC (US) 2022-02-24 US disclosed
US-10980807-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) INVENTISBIO LLC (US) 2021-04-20 US disclosed
US-20200046697-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC 2020-02-13 US disclosed
WO-2017139414-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO INC. (KY) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338373-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885ALDH1A1 801/4885
US-20220054486-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885ALDH1A1 801/4885
US-20200046697-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885ALDH1A1 801/4885
US-10980807-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885ALDH1A1 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.